RecruitingPhase 2NCT07104565
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Incyte Medical MonitorIncyte Corporation
- Intervention
- INCA000585(drug)
- Enrollment
- 56 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (30)
- Palo Verde Cancer Specialists Palo Verde Hematology Oncology, Ltd Glendale, Glendale, Arizona, United States
- Usc Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Gnp Research, Cooper City, Florida, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Montefiore Medical Center, The Bronx, New York, United States
- Inova Schar Cancer Institute, Fairfax, Virginia, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
- Versiti Bloodcenter of Wisconsin Bcw Milwaukee, Milwaukee, Wisconsin, United States
- St Vincent'S Hospital Sydney, Darlinghurst, New South Wales, Australia
- Townsville University Hospital, Douglas, Queensland, Australia
- Princess Alexandra Hospital Australia, Woolloongabba, Queensland, Australia
- Box Hill Hospital, Box Hill, Victoria, Australia
- Monash Medical Centre Clayton, Clayton, Victoria, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07104565 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE1, PHASE2NCT07175493A Study of CM336 in Patients With Relapsed or Refractory Autoimmune CytopeniaKeymed Biosciences Co.Ltd